quinoxalines has been researched along with eye in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.33) | 18.7374 |
| 1990's | 7 (23.33) | 18.2507 |
| 2000's | 13 (43.33) | 29.6817 |
| 2010's | 7 (23.33) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cynader, MS; Matsuo, T | 1 |
| Aizenman, E; Loring, R; Rosenberg, PA; Xie, Y; Zaleskas, V | 1 |
| Chien, DS; Gluchowski, C; Homsy, JJ; Tang-Liu, DD | 1 |
| Crosson, CE; Heath, AR; Ogidigben, MJ; Potter, DE | 1 |
| Burke, JA; Potter, DE | 1 |
| Acheampong, AA; Shackleton, M; Tang-Liu, DD | 1 |
| Dhanjil, S; Lachkar, Y; Migdal, C | 1 |
| Babighian, S; Bonomi, L; Marchini, G; Tosi, R | 1 |
| Cantatore, F; Cardia, L; Maino, A; Ruggeri, G; Vetrugno, M | 1 |
| Martin, W; McNeish, AJ; Wilson, WS | 1 |
| Miller, J; Uttamchandani, D; Wilson, CG | 1 |
| Acheampong, AA; Burke, J; John, B; Shackleton, M; Tang-Liu, D; Wheeler, L | 1 |
| Bunce, C; Garway-Heath, DF; Hitchings, RA; Indar, A; Poinoosawmy, D | 1 |
| Cheng, CY; Chou, JC; Hsu, WM; Ko, YC; Liu, CJ; Liu, JH | 1 |
| Cheng, CY; Chiu, AW; Chou, JC; Hsu, WM; Ko, YC; Liu, CJ; Liu, JH | 1 |
| Ermis, SS; Inan, UU; Oztürk, F; Yücel, A | 1 |
| Avilés-Trigueros, M; García-Avilés, A; Lafuente, MP; Mayor-Torroglosa, S; Miralles de Imperial, J; Rodríguez, ME; Vidal-Sanz, M; Villegas-Pérez, MP | 1 |
| Asagidag, A; Celik, A; Ermis, SS; Inan, UU; Onrat, E; Orman, A; Ozturk, F; Yucel, A | 1 |
| Conkbayir, I; Simsek, T; Yanik, B; Zilelioglu, O | 1 |
| Abdulrazik, M; Benita, S; Tamilvanan, S | 1 |
| Chappa, AK; Jiang, S; Proksch, JW | 1 |
| Alldredge, B; Gerhardt, G; Halverson, K; Pensyl, D; Qualls, C; Sullivan-Mee, M | 1 |
| Shinde, UA; Singh, KH | 1 |
| Abrams, L; Cantor, L; Ehrlich, R; Harris, A; Hollander, DA; Rusia, D; Shoja, MM; Shoshani, Y; Siesky, B; Williams, JM | 1 |
| Geethalakshmi, A; Jha, SK; Karki, R; Nikunj, B; Venkatesh, DP | 1 |
| Garhöfer, G; Hommer, A; Popa-Cherecheanu, A; Qiao, C; Resch, H; Schmetterer, L; Sperl, P | 1 |
| Feke, GT; Pasquale, LR; Rhee, DJ; Turalba, AV | 1 |
| Fedorchak, MV; Little, SR; Mealy, JE | 1 |
| Attar, M; Luu, KT; Tamhane, M | 1 |
| Del Amo, EM; Ranta, VP; Urtti, A | 1 |
10 trial(s) available for quinoxalines and eye
| Article | Year |
|---|---|
Effect of brimonidine tartrate on ocular hemodynamic measurements.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Blood Flow Velocity; Brimonidine Tartrate; Ciliary Arteries; Cross-Over Studies; Double-Blind Method; Eye; Hemodynamics; Humans; Intraocular Pressure; Middle Aged; Ocular Hypertension; Ophthalmic Artery; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Retinal Artery; Ultrasonography, Doppler, Color | 1998 |
Effects of 0.2% brimonidine on ocular anterior structures.
Topics: Adrenergic alpha-Agonists; Adult; Brimonidine Tartrate; Eye; Female; Humans; Intraocular Pressure; Male; Prospective Studies; Pupil; Quinoxalines; Ultrasonography; Visual Acuity | 1999 |
Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma.
Topics: Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Eye; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Prostaglandins F, Synthetic; Pulsatile Flow; Quinoxalines | 2002 |
Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Brimonidine Tartrate; Cross-Over Studies; Drug Evaluation; Eye; Female; Glaucoma, Open-Angle; Heart Rate; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Optic Disk; Optic Nerve Diseases; Prostaglandins F, Synthetic; Quinoxalines; Vision Disorders; Visual Fields | 2002 |
The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial.
Topics: Blood Flow Velocity; Brimonidine Tartrate; Ciliary Arteries; Eye; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ocular Hypertension; Ophthalmic Artery; Prostaglandins F, Synthetic; Quinoxalines; Retinal Artery; Ultrasonography, Doppler, Color; Vascular Resistance | 2003 |
The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol.
Topics: Administration, Topical; Adult; Amides; Betaxolol; Bimatoprost; Brimonidine Tartrate; Cardiovascular System; Cloprostenol; Cross-Over Studies; Double-Blind Method; Eye; Humans; Intraocular Pressure; Lipids; Male; Ocular Hypotension; Prospective Studies; Pulmonary Circulation; Quinoxalines; Regional Blood Flow; Travoprost | 2004 |
Comparative analysis of the effects of brimonidine and dorzolamide on ocular blood flow velocity in patients with newly diagnosed primary open-angle glaucoma.
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Brimonidine Tartrate; Eye; Female; Glaucoma, Open-Angle; Heart Rate; Humans; Instillation, Drug; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Sulfonamides; Thiophenes; Treatment Outcome; Ultrasonography, Doppler, Color | 2006 |
Short-term effects of brimonidine/timolol and dorzolamide/timolol on ocular perfusion pressure and blood flow in glaucoma.
Topics: Administration, Ophthalmic; Aged; Antihypertensive Agents; Blood Pressure; Brimonidine Tartrate; Cross-Over Studies; Double-Blind Method; Drug Combinations; Eye; Female; Glaucoma, Open-Angle; Hemodynamics; Humans; Intraocular Pressure; Male; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Tonometry, Ocular | 2012 |
A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
Topics: Aged; Antihypertensive Agents; Blood Flow Velocity; Brimonidine Tartrate; Cross-Over Studies; Double-Blind Method; Drug Combinations; Eye; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Laser-Doppler Flowmetry; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Time Factors; Timolol; Ultrasonography, Doppler, Color | 2012 |
Effects of dorzolamide-timolol and brimonidine-timolol on retinal vascular autoregulation and ocular perfusion pressure in primary open angle glaucoma.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Drug Combinations; Eye; Female; Glaucoma, Open-Angle; Homeostasis; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Quinoxalines; Regional Blood Flow; Sulfonamides; Thiophenes; Timolol | 2013 |
20 other study(ies) available for quinoxalines and eye
| Article | Year |
|---|---|
Localization of alpha-2 adrenergic receptors in the human eye.
Topics: Adrenergic alpha-Agonists; Aged; Autoradiography; Brimonidine Tartrate; Eye; Female; Humans; Ligands; Male; Middle Aged; Quinoxalines; Receptors, Adrenergic, alpha | 1992 |
2,4,5-trihydroxyphenylalanine in solution forms a non-N-methyl-D-aspartate glutamatergic agonist and neurotoxin.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Cells, Cultured; Cerebral Cortex; Chickens; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Eye; In Vitro Techniques; Neurons; Neurotoxins; Ocular Physiological Phenomena; Quinoxalines; Rats | 1991 |
Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes.
Topics: Absorption; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Chromatography, High Pressure Liquid; Clonidine; Conjunctiva; Cornea; Eye; Female; Perfusion; Permeability; Quinoxalines; Rabbits; Sclera; Solubility; Tissue Distribution | 1990 |
Functional evidence for heterogeneity of ocular alpha 2-adrenoceptors.
Topics: Anesthesia; Animals; Brimonidine Tartrate; Cats; Ciliary Body; Cyclic AMP; Dose-Response Relationship, Drug; Eye; Imidazoles; In Vitro Techniques; Iris; Isoproterenol; Medetomidine; Quinoxalines; Rabbits; Receptors, Adrenergic, alpha; Vasoactive Intestinal Peptide | 1990 |
Ocular effects of a relatively selective alpha 2 agonist (UK-14, 304-18) in cats, rabbits and monkeys.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cats; Cebus; Eye; Female; Intraocular Pressure; Male; Neurons; Ocular Hypertension; Pupil; Quinoxalines; Rabbits; Water | 1986 |
Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
Topics: Adrenergic alpha-Agonists; Albinism, Oculocutaneous; Animals; Brimonidine Tartrate; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Eye; Female; Ophthalmic Solutions; Pigment Epithelium of Eye; Quinoxalines; Rabbits | 1995 |
Acute and chronic effects of brimonidine 0.2% on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: an open-label, uncontrolled, prospective study.
Topics: Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Drug Administration Schedule; Eye; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Pulsatile Flow; Quinoxalines; Time Factors | 2001 |
Dominant role of an endothelium-derived hyperpolarizing factor (EDHF)-like vasodilator in the ciliary vascular bed of the bovine isolated perfused eye.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Animals; Barium; Biological Factors; Blood Vessels; Bradykinin; Cattle; Charybdotoxin; Ciliary Body; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Eye; Flurbiprofen; Glyburide; In Vitro Techniques; NG-Nitroarginine Methyl Ester; Ouabain; Oxadiazoles; Perfusion; Potassium; Potassium Channel Blockers; Pressure; Quinoxalines; Tetraethylammonium; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2001 |
Minimally invasive spectroscopic system for intraocular drug detection.
Topics: Adrenergic alpha-Agonists; Anterior Chamber; Anti-Bacterial Agents; Aqueous Humor; Brimonidine Tartrate; Contact Lenses; Contact Lenses, Hydrophilic; Contrast Media; Equipment Design; Eye; Fluorescein; Humans; Quinoxalines; Spectrum Analysis; Tetracycline | 2002 |
Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes.
Topics: Administration, Topical; Animals; Brimonidine Tartrate; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Eye; Injections, Intraperitoneal; Iris; Macaca fascicularis; Metabolic Clearance Rate; Quinoxalines; Rabbits; Rats; Tissue Distribution; Vitreous Body | 2002 |
Effect of treatment by medicine or surgery on intraocular pressure and pulsatile ocular blood flow in normal-pressure glaucoma.
Topics: Administration, Topical; Aged; Antihypertensive Agents; Betaxolol; Blood Flow Velocity; Brimonidine Tartrate; Eye; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Ophthalmic Solutions; Prostaglandins F, Synthetic; Pulsatile Flow; Quinoxalines; Retrospective Studies; Tonometry, Ocular; Trabeculectomy | 2002 |
Transient ischemia of the retina results in massive degeneration of the retinotectal projection: long-term neuroprotection with brimonidine.
Topics: Afferent Pathways; Animals; Axonal Transport; Brain Stem; Brimonidine Tartrate; Cholera Toxin; Eye; Female; Functional Laterality; Image Processing, Computer-Assisted; Immunohistochemistry; Ischemia; Mesencephalon; Nerve Degeneration; Neuroprotective Agents; Quinoxalines; Rats; Rats, Sprague-Dawley; Retina; Retinal Ganglion Cells; Staining and Labeling | 2003 |
Non-systemic delivery of topical brimonidine to the brain: a neuro-ocular tissue distribution study.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Animals; Brain; Brimonidine Tartrate; Data Interpretation, Statistical; Drug Delivery Systems; Eye; Functional Laterality; Male; Optic Nerve; Quinoxalines; Rabbits; Tissue Distribution; Visual Pathways | 2006 |
A rapid and sensitive LC/MS/MS assay for the quantitation of brimonidine in ocular fluids and tissues.
Topics: Adrenergic alpha-Agonists; Animals; Aqueous Humor; Brimonidine Tartrate; Chromatography, Liquid; Ciliary Body; Drug Stability; Eye; Iris; Linear Models; Quinoxalines; Rabbits; Reference Standards; Reproducibility of Results; Retina; Sensitivity and Specificity; Tandem Mass Spectrometry; Vitreous Body | 2009 |
Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Eye; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Treatment Outcome | 2010 |
Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Calorimetry, Differential Scanning; Chitosan; Delayed-Action Preparations; Drug Compounding; Drug Delivery Systems; Electrochemistry; Excipients; Eye; Freeze Drying; Intraocular Pressure; Irritants; Membranes; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Ophthalmic Solutions; Particle Size; Quinoxalines; Rabbits; Solubility; Spectroscopy, Fourier Transform Infrared | 2011 |
Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system.
Topics: Animals; Biological Availability; Brimonidine Tartrate; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Delivery Systems; Drug Stability; Eye; Gels; Glaucoma; Hydrogen-Ion Concentration; Ions; Ophthalmic Solutions; Polysaccharides, Bacterial; Quinoxalines; Rabbits | 2012 |
In vitro characterization of a controlled-release ocular insert for delivery of brimonidine tartrate.
Topics: Animals; Brimonidine Tartrate; Cell Death; Delayed-Action Preparations; Drug Delivery Systems; Epithelial Cells; Eye; Humans; Lactic Acid; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinoxalines | 2014 |
Response to Comments on
Topics: Animals; Brimonidine Tartrate; Drug Delivery Systems; Eye; Haplorhini; Quinoxalines | 2022 |
Comments on
Topics: Adrenergic alpha-Agonists; Animals; Antihypertensive Agents; Brimonidine Tartrate; Drug Delivery Systems; Eye; Haplorhini; Intraocular Pressure; Ophthalmic Solutions; Quinoxalines | 2022 |